Biblio

Found 65 results
Author Keyword Title Type [ Year(Asc)]
Filters: Author is Ignace B Vergote  [Clear All Filters]
2015
A. M. Poveda, Selle, F., Hilpert, F., Reuss, A., Savarese, A., Vergote, I. B., Witteveen, P., Bamias, A., Scotto, N., Mitchell, L., and Pujade-Lauraine, E., Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial., J Clin Oncol, vol. 33, no. 32, p. 3838, 2015.
S. Mahner, Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., Vergote, I. B., Vasey, P. A., Pujade-Lauraine, E., Gladieff, L., and Ferrero, A., Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial., Eur J Cancer, vol. 51, no. 3, pp. 352-8, 2015.
E. Despierre, Vergote, I. B., Anderson, R., Coens, C., Katsaros, D., Hirsch, F. R., Boeckx, B., Varella-Garcia, M., Ferrero, A., Ray-Coquard, I., Berns, E. M. J. J., Casado, A., Lambrechts, D., and Jimeno, A., Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy., Target Oncol, vol. 10, no. 4, pp. 583-96, 2015.
C. Khoon Lee, Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A. - C., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I. B., Scambia, G., Ferrero, A., Harter, P., Pujade-Lauraine, E., and Friedlander, M. Leonard, Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial., Gynecol Oncol, vol. 136, no. 1, pp. 18-24, 2015.
A. Floquet, Vergote, I. B., Colombo, N., Fiane, B., Monk, B. J., Reinthaller, A., Calvert, P., Herzog, T. J., Meier, W., Kim, J. - W., Del Campo, J. M., Friedlander, M. Leonard, Pisano, C., Isonishi, S., Crescenzo, R. J., Barrett, C., Wang, K., Mitrica, I., and du Bois, A., Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial., Gynecol Oncol, vol. 136, no. 1, p. 42, 2015.
2014
E. Pujade-Lauraine, Hilpert, F., Weber, B., Reuss, A., Poveda, A. M., Kristensen, G. B., Sorio, R., Vergote, I. B., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. Raza, Follana, P., Bollag, D., and Ray-Coquard, I., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial., J Clin Oncol, vol. 32, no. 13, p. 1308, 2014.
A. du Bois, Floquet, A., Kim, J. - W., Rau, J., Del Campo, J. M., Friedlander, M. Leonard, Pignata, S., Fujiwara, K., Vergote, I. B., Colombo, N., Mirza, M. R., Monk, B. J., Kimmig, R., Ray-Coquard, I., Zang, R., Diaz-Padilla, I., Baumann, K. H., Mouret-Reynier, M. - A., Kim, J. - H., Kurzeder, C., Lesoin, A., Vasey, P. A., Marth, C., Canzler, U., Scambia, G., Shimada, M., Calvert, P., Pujade-Lauraine, E., Kim, B. - G., Herzog, T. J., Mitrica, I., Schade-Brittinger, C., Wang, Q., Crescenzo, R. J., and Harter, P., Incorporation of pazopanib in maintenance therapy of ovarian cancer., J Clin Oncol, vol. 32, no. 30, p. 3382, 2014.
I. B. Vergote, Jimeno, A., Joly, F., Katsaros, D., Coens, C., Despierre, E., Marth, C., Hall, M., Steer, C. B., Colombo, N., Lesoin, A., Casado, A., Reinthaller, A., Green, J. A., Buck, M., Ray-Coquard, I., Ferrero, A., Favier, L., Reed, N. Simon, Curé, H., and Pujade-Lauraine, E., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a EORTC GCG, and GCIG study., J Clin Oncol, vol. 32, no. 4, pp. 320-6, 2014.
2013
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
K. D. Steffensen, Waldstrom, M., Pallisgard, N., Lund, B., Bergfeldt, K., Wihl, J., Keldsen, N., Marth, C., Vergote, I. B., and Jakobsen, A., Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study, Int J Gynecol Cancer, vol. 23, pp. 73-80, 2013.
F. A. Raja, Counsell, N., Colombo, N., Pfisterer, J., du Bois, A., Parmar, M. K. B., Vergote, I. B., Gonzalez-Martin, A., Alberts, D. S., Plante, M., Torri, V., and Ledermann, J. A., Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data., Ann Oncol, vol. 24, no. 12, pp. 3028-34, 2013.
C. Khoon Lee, Simes, R. J., Brown, C., Gebski, V., Pfisterer, J., Swart, A. Marie, Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., Schauer, C., Pisano, C., Parma, G., Baumann, K. H., Ledermann, J. A., Pujade-Lauraine, E., Bentley, J., Kristensen, G. B., Belau, A., Nankivell, M., Canzler, U., Lord, S. J., Kurzeder, C., and Friedlander, M. Leonard, A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer., Ann Oncol, vol. 24, no. 4, p. 943, 2013.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
2012
J. Alexandre, Brown, C., Coeffic, D., Raban, N., Pfisterer, J., Maenpaa, J. U., Chalchal, H., Fitzharris, B., Volgger, B., Vergote, I. B., Pisano, C., Ferrero, A., and Pujade-Lauraine, E., CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial., Br J Cancer, vol. 106, no. 4, p. 637, 2012.
A. Casado, Penninckx, B., Reed, N. Simon, van der Burg, M. E. L., Berns, E. M. J. J., Katsaros, D., Ferrero, A., Fernando, M., Jimeno, A., Vermorken, J. B., Pecorelli, S., and Vergote, I. B., EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials. , European Journal Cancer , vol. 10, no. 1, p. 73, 2012.
U. Wagner, Marth, C., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I. B., Piccirillo, M. C., Fossati, R., Gebski, V., and Lauraine, E. P., Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients., Br J Cancer, vol. 107, no. 4, p. 591, 2012.
K. Lindemann, Christensen, R. D., Vergote, I. B., Stuart, G. C. E., Izquierdo, M. A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A. B., Hirte, H., Åvall-Lundqvist, E., Vrdoljak, E., Green, J. A., and Kristensen, G. B., First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG., Ann Oncol, vol. 23, no. 10, pp. 2613-9, 2012.
2011
M. Leonard Friedlander, Trimble, E. L., Tinker, A., Alberts, D. S., Åvall-Lundqvist, E., Brady, M. F., Harter, P., Pignata, S., Pujade-Lauraine, E., Sehouli, J., Vergote, I. B., Beale, P., Bekkers, R., Calvert, P., Copeland, L., Glasspool, R. M., Gonzalez-Martin, A., Katsaros, D., Kim, J. Won, Miller, B., Provencher, D. M., Rubinstein, L., Atri, M., Zeimet, A. G., Bacon, M., Kitchener, H. C., and Stuart, G. C. E., Clinical trials in recurrent ovarian cancer., Int J Gynecol Cancer, vol. 21, no. 4, pp. 771-5, 2011.
F. Joly, Ray-Coquard, I., Fabbro, M., Donoghoe, M., Boman, K., Sugimoto, A., Vaughan, M., Reinthaller, A., Vergote, I. B., Ferrandina, G., Dell'Anna, T., Huober, J., and Pujade-Lauraine, E., Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial., Gynecol Oncol, vol. 122, no. 2, p. 232, 2011.
G. J. S. Rustin, Vergote, I. B., Eisenhauer, E., Pujade-Lauraine, E., Quinn, M., Thigpen, T., du Bois, A., Kristensen, G. B., Jakobsen, A., Sagae, S., Greven, K., Parmar, M. K. B., Friedlander, M. Leonard, Cervantes, A., Vermorken, J. B., and Intergroup, G. Cancer, Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG), Int J Gynecol Cancer, vol. 21, pp. 419-23, 2011.
L. C, Simes, R. J., Gebski, V., Wollschlaeger, K., Plante, M., Vergote, I. B., Maenpaa, J. U., Ferrero, A., Pisano, C., Parma, G., Berton-Rigaud, D., der W, S., Bentley, J., Reinthaller, A., Schmalfeldt, B., Hirte, H., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Development and validation of a nomogram to predict survival in CALYPSO and AGO-2.5 patients with platinum sensitive recurrent ovarian cancer. , Int J Gynecol Cancer , vol. 21, no. 12 Suppl 3, 2011.
C. Kurzeder, L, Z., Eisenhauer, E., Vergote, I. B., du Bois, A., D, T., Y, W., JF, G., HW, H., B, R., LC, H., Bentley, J., Wagner, U., Plante, M., Kimmig, R., and Pfisterer, J., The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. , J Clin Oncol , vol. 29, no. suppl; abstr 5088, 2011.
C. Khoon Lee, Simes, R. J., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I. B., Pisano, C., Parma, G., Burges, A., Bourgeois, H., Högberg, T., Bentley, J., Angleitner-Boubenizek, L., Ferrero, A., Richter, B., Hirte, H., Gebski, V., Pfisterer, J., Pujade-Lauraine, E., and Friedlander, M. Leonard, Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer., Br J Cancer, vol. 105, no. 8, pp. 1144-50, 2011.

Pages